About this trial
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
Eligibility criteria
Qualifiers
Adult patients (age ≥18 years)
Critically ill patients with dialysis-dependent AKI
Continuous renal replacement therapy (CRRT)
Written informed consent
Disqualifiers
Chronic kidney disease with estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2
Chronic dialysis dependency
Kidney transplant
(Glomerulo-)nephritis, interstitial nephritis, vasculitis
Trial design
Treatments tested in this trial
- Critically ill patients with continuous renal replacement therapy
Treatment groups
Sponsors and collaborators
University Hospital Muenster
Lead sponsor
Baxter Healthcare Corporation
Collaborator